Investigational drug · Phase 2
BMN 351
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Duchenne Muscular Dystrophy (DMD), Duchenne Muscular Dystrophy.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "BMN 351"
First trial start
2024
Jan 3, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BMN 351", any sponsor or status.
Conditions studied
As listed on its trial records.
- Duchenne Muscular Dystrophy (DMD)
- Duchenne Muscular Dystrophy
Approved drugs for the same conditions: Duchenne muscular dystrophy · Neurology · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "BMN 351" as an intervention, largest first.
- An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular DystrophyEnrolling by invitation
BioMarin PharmaceuticalBioMarin (BMRN)
NCT07573631 · 18 participants (planned) · Start Apr 20, 2026 · Primary completion Dec 2031
Drug: BMN 351 · For: Duchenne Muscular Dystrophy (DMD)
Sites: Milan, Italy; Rome, Italy; Leiden, Netherlands · 6 sites in all
- A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular DystrophyActive, not recruiting
BioMarin PharmaceuticalBioMarin (BMRN)
NCT06280209 · 18 participants · Start Jan 3, 2024 · Primary completion Apr 14, 2027
Drug: BMN 351 · For: Duchenne Muscular Dystrophy
Sites: Milan, Italy; Rome, Italy; Leiden, Netherlands · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Targeting a Novel Site in Exon 51 with Antisense Oligonucleotides Induces Enhanced Exon Skipping in a Mouse Model of Duchenne Muscular Dystrophy.
Oppeneer T, Qi Y, Henshaw J, et al. · Nucleic Acid Ther 2025
- BMN 351-Induced Exon Skipping and Dystrophin Expression in Skeletal and Cardiac Muscle Lead to Preservation of Motor Function in a Mouse Model of Exon 51 Skip-Amenable Duchenne Muscular Dystrophy.
Oppeneer T, Qi Y, Henshaw J, et al. · Nucleic Acid Ther 2025
Also in development for Duchenne Muscular Dystrophy (DMD)
- Zeleciment RostudirsenDYNE-251Phase 32 trials
Dyne Therapeutics · Duchenne Muscular Dystrophy (DMD), Muscular Dystrophy, Duchenne, Muscular Dystrophy (DMD)
- BrogidirsenNS-089, NCNP-02Phase 23 trials
NS Pharma, Inc. · Duchenne Muscular Dystrophy, Exon 44, DMD
- ENTR-601-44Phase 22 trials
Entrada Therapeutics, Inc. · Duchenne Muscular Dystrophy (DMD)
- ENTR-601-45Phase 22 trials
Entrada Therapeutics, Inc. · Duchenne Muscular Dystrophy (DMD)
- SAT-3247Phase 22 trials
Satellos Bioscience, Inc. · Duchenne Muscular Dystrophy, Duchenne, DMD
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from BioMarin.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.